Apolipoprotein E and Carotid Artery Atherosclerosis

The Rotterdam Study

A.J.C. Slooter, MD, PhD; M.L. Bots, MD, PhD; L.M. Havekes, PhD; A. Iglesias del Sol, MD; M. Cruts, PhD; D.E. Grobbee, MD, PhD; A. Hofman, MD, PhD; C. Van Broeckhoven, PhD; J.C.M. Witteman, PhD; C.M. van Duijn, PhD

Background and Purpose—Carotid artery atherosclerosis is a strong predictor for future stroke. It is yet unclear whether the apolipoprotein E polymorphism (APOE) is related to atherosclerosis in the carotid arteries. The aim of the present study was to investigate the role of APOE in carotid artery atherosclerosis.

Methods—A population-based cross-sectional study was performed on 5401 subjects. Atherosclerosis was noninvasively assessed by the common carotid artery intima-media wall thickness and the presence of plaques in the carotid arteries. The relationship of the 6 APOE genotypes with these 2 indicators was studied with linear and logistic regression analysis, respectively, with adjustments for age and sex.

Results—Carriers of the E2E3 genotype had a thinner intima-media wall thickness (mean difference, \(-0.02 \text{ mm}; 95\% \text{ CI, } -0.03 \text{ to } -0.01 \text{ mm}\) and fewer plaques (odds ratio for \(>3\) plaques at 6 sites, 0.6; 95\% CI, 0.4 to 0.8) than the most common group, E3E3. The E4E4 group had slightly more atherosclerosis, but this was not statistically significant. Adjusting for the level of the apolipoprotein E protein (apoE) in serum or total or HDL cholesterol did not essentially change these findings.

Conclusions—Our results suggest that APOE*4 is not an important risk factor for carotid artery atherosclerosis. The inverse relationship of E2E3 with carotid artery atherosclerosis seems to be independent of serum apoE and total and HDL cholesterol levels. However, the low frequency, together with the small effects, implies that any protective effect of E2E3 on carotid artery atherosclerosis is limited. (Stroke. 2001;32:1947-1952.)

Key Words: apolipoproteins ■ atherosclerosis ■ carotid arteries ■ genetics ■ polymorphism (genetics)

High levels of total and LDL cholesterol and low levels of HDL cholesterol predispose to the development of atherosclerosis. Serum levels of these lipids are partly determined by the apolipoprotein E genotype (APOE). The APOE gene has 3 common alleles, APOE*2, APOE*3, and APOE*4, which fully determine the protein isoforms apoE2, apoE3, and apoE4, respectively, and partly determine the level of apolipoprotein E protein (apoE) in serum. Compared with APOE*3 homozygotes, the most common genotype, APOE*2, is associated with lower levels of total and LDL cholesterol and with higher levels of HDL cholesterol, while APOE*4 has opposite effects. ApoE plays a pivotal role in the transport of lipoproteins and is involved in numerous processes in the arterial wall.

Research on the APOE polymorphism and stroke has been inconclusive, but many of the studies were heterogeneous and small. Because ultrasonographically assessed atherosclerosis in the carotid arteries strongly predicts a future stroke, studies of these traits can efficiently be used to study stroke risk factors. Additionally, studies on APOE and carotid artery atherosclerosis have yielded inconsistent results. Again, several investigations were relatively small. Since most studies were not population-based and excluded subjects at high risk of atherosclerosis, selection bias may have occurred. None of the previous studies evaluated an association between APOE and atherosclerotic plaques, while not more than 1 study explored the role of serum apoE level in carotid atherosclerosis.

A putative relation between APOE and atherosclerosis could result either from differences in function of the isoforms or from differences in serum levels. The aim of this study was to investigate, in the general population of elderly, the association of the APOE genotype with atherosclerosis in carotid arteries, while considering the role of serum apoE level and total and HDL cholesterol.
Subjects and Methods

Population

This study is part of the Rotterdam Study, a population-based, single-center cohort study on chronic and disabling diseases in the elderly. The design of the study has been described previously.22 Informed consent was obtained from all subjects, and the study was approved by the medical ethics committee of Erasmus Medical Center. All inhabitants of a suburb of Rotterdam, aged at least 55 years, including people living in homes for the elderly, were invited to participate. In total, 7983 participants (response rate, 78%) were included (1990–1993). Blood was taken from 7041 participants of the Rotterdam Study (88%). APOE genotyping was performed in all subjects who donated blood (n = 6852; 86% of the cohort). Failure to determine the APOE genotype resulted mainly from inadequate storage of buffy coats from leukocytes and was random. Ultrasonography of the carotid arteries was performed in 5854 participants (73%), of whom 5401 subjects had a known APOE genotype. Of these, 4273 persons had complete assessment on atherosclerotic plaques at both sides of the common carotid arteries, the carotid artery bifurcations, and the internal carotid arteries was estimated by odds ratios (OR) with 95% CI with the use of multiple logistic regression models. Moreover, because plaques were assessed at 3 sides in the carotid arterial tree, at both the left and the right sides, the minimum number of plaques was 0, and the maximum number was 6. Because there is not further strong evidence to assume an association between APOE and atherosclerosis at 1 particular side, the study population was categorized into those without any plaques, persons with 1 to 3 plaques, and subjects with 4 to 6 plaques to explore a possible dose-response relationship. In the analyses of the ORs for 1 to 3 plaques, subjects with 4 to 6 plaques were excluded. Similarly, when we analyzed the outcome for 4 to 6 plaques, we excluded subjects with 1 to 3 plaques. The E3E3 group was used as a reference in all analyses.

To adjust for confounding, age and sex were included in all models. To explore any effects of APOE, independent of total and HDL cholesterol, we added these factors to the model. Furthermore, we built models with the APOE genotypes and the following cardiovascular risk factors: systolic blood pressure, diastolic blood pressure, diabetes mellitus, body mass index, smoking, and total and HDL cholesterol to study effects of APOE irrespective of these variables. Moreover, to investigate the role of serum apoE level in the association of the APOE genotypes and atherosclerosis, the study population was restricted to subjects in whom the level of apoE in serum was determined, and models were compared with and without serum apoE level (entered as a continuous variable).

In addition, to explore an association of the level of serum apoE and carotid artery plaques, logistic regression analysis was used, and linear regression models were used to study the relationship of apoE level and intima-media thickness. Serum apoE levels was entered as a continuous variable, and these analyses were also adjusted for age and sex.

The percentage of explained variance was estimated by the squared adjusted multiple correlation coefficient.27 The Pearson’s $r^2$
**APOE and Carotid Artery Plaques**

We found similar relationships of APOE and plaques in the common carotid arteries, the carotid artery bifurcations, and the internal carotid arteries. Carriers of the E2E3 genotype had a lower prevalence of plaques at all 3 sites (age- and sex-adjusted ORs, all 0.8) compared with the E3E3 group. Carriership of an APOE*4 allele was not associated with the presence of plaques. We further analyzed the total number of plaques at all sides to increase statistical power. As shown in Table 3, there was no association between APOE and the intermediate number of plaques. However, the prevalence of >3 plaques was decreased in carriers of E2E3 (OR, 0.6; 95% CI, 0.4 to 0.8; \( P=0.003 \)) and increased in persons with E4E4, albeit this was not statistically significant (OR, 1.4; 95% CI, 0.8 to 2.4; \( P=0.21 \)). In men we found an increased OR for the E2E2 genotype, but this was not statistically significant either (OR, 2.7; 95% CI, 0.6 to 12.1; \( P=0.19 \)). No other major differences were observed across sex or categories of age. Adjusting for total cholesterol and HDL cholesterol or for the aforementioned cardiovascular risk factors did not essentially change our findings (latter not shown).

**APOE and Intima-Media Thickness**

The median common carotid artery intima-media wall thickness in the E3E3 group was 0.77 mm (10th centile, 0.63; 90th centile, 1.00 mm). Compared with this reference group, carriers of E2E2 or E2E3 had a thinner intima-media wall thickness, particularly among men (Table 2). Among men we found further that carriers of E2E4 or E4E4 had a slightly increased common carotid artery intima-media wall thickness than persons with E3E3, but this was not statistically significant (\( P=0.32 \) and \( P=0.21 \), respectively). Findings were comparable after stratification according to age. When total and HDL cholesterol were added to the model, or when we further adjusted or stratified on the cardiovascular risk factors as defined above, our observations did not change.

### Table 2. Difference in Common Carotid Artery Intima-Media Thickness by APOE Genotypes

<table>
<thead>
<tr>
<th>Genotype</th>
<th>All Model 1</th>
<th>All Model 2</th>
<th>Men Model 1</th>
<th>Men Model 2</th>
<th>Women Model 1</th>
<th>Women Model 2</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>n=46</td>
<td>n=704</td>
<td>n=137</td>
<td>n=3122</td>
<td>n=1258</td>
<td>n=134</td>
</tr>
<tr>
<td>E2E2</td>
<td>-0.04 (-0.08 to 0.00)*</td>
<td>-0.02 (-0.03 to 0.01)*</td>
<td>-0.01 (-0.03 to 0.02)</td>
<td>0 (reference)</td>
<td>0.00 (-0.01 to 0.01)</td>
<td>0.01 (-0.01 to 0.04)</td>
</tr>
<tr>
<td>E2E3</td>
<td>-0.04 (-0.08 to 0.00)</td>
<td>-0.01 (-0.03 to 0.00)*</td>
<td>0.00 (-0.03 to 0.02)</td>
<td>0 (reference)</td>
<td>0.00 (-0.01 to 0.01)</td>
<td>0.01 (-0.02 to 0.03)</td>
</tr>
<tr>
<td>E2E4</td>
<td>-0.01 (-0.02 to 0.00)</td>
<td>-0.02 (-0.05 to 0.01)</td>
<td>-0.02 (-0.05 to 0.01)</td>
<td>0 (reference)</td>
<td>0.00 (-0.01 to 0.01)</td>
<td>0.00 (-0.02 to 0.03)</td>
</tr>
<tr>
<td>E3E3</td>
<td>-0.01 (-0.02 to 0.01)</td>
<td>-0.02 (-0.05 to 0.01)</td>
<td>-0.02 (-0.05 to 0.01)</td>
<td>0 (reference)</td>
<td>0.00 (-0.01 to 0.01)</td>
<td>0.00 (-0.03 to 0.03)</td>
</tr>
<tr>
<td>E3E4</td>
<td>-0.01 (-0.02 to 0.01)</td>
<td>-0.02 (-0.05 to 0.01)</td>
<td>-0.02 (-0.05 to 0.01)</td>
<td>0 (reference)</td>
<td>0.00 (-0.01 to 0.01)</td>
<td>0.00 (-0.04 to 0.03)</td>
</tr>
<tr>
<td>E4E4</td>
<td>-0.01 (-0.02 to 0.01)</td>
<td>-0.02 (-0.05 to 0.01)</td>
<td>-0.02 (-0.05 to 0.01)</td>
<td>0 (reference)</td>
<td>0.00 (-0.01 to 0.01)</td>
<td>0.00 (-0.06 to 0.01)</td>
</tr>
</tbody>
</table>

Values are mean difference with E3E3 group in mm with 95% CIs, adjusted for age and sex (model 1) or age, sex, and total and HDL cholesterol (model 2).

*Significantly different from E3E3 group: \( P<0.05 \).

statistic was used for categorical data, and an ANOVA was applied to continuous, normally distributed variables. In case of missing data for possible confounders or intermediate factors, the most likely value was imputed on the basis of age and sex.

**Results**

The distribution of the APOE polymorphism in our study population was in Hardy-Weinberg equilibrium (E2E2, 0.9% \([n=46]\); E2E3, 13.0% \([n=704]\); E2E4, 2.5% \([n=137]\); E3E3, 57.8% \([n=3122]\); E3E4, 23.3% \([n=1258]\); and E4E4, 2.5% \([n=134]\); \( \chi^2=1.5, df=3, P=0.35 \)). Descriptive statistics are presented in Table 1. Total and HDL cholesterol differed across the APOE genotypes (E2E2 \( n=518 \), E2E3 \( n=570 \), E2E4 \( n=570 \), E2E3 \( n=570 \), E3E3 \( n=570 \), E4E4 \( n=570 \)). Compared with the E3E3 group, total cholesterol was higher in E3E3 and in E4E4 carriers and lower in carriers of E2E2 or E2E3. HDL cholesterol, by contrast, was highest in subjects with the E2E3 genotype and lower in persons with E3E4 or E4E4. The APOE genotype explained 27% of the variance in serum apoE levels. Serum apoE level was highest in E2E2 carriers, intermediate in subjects with E3E3, and lowest in carriers of the E4E4 genotype (E2E3 \( n=1833 \), E4E4 \( n=1833 \), E3E3 \( n=448 \), E2E2 \( n=448 \)). No other major differences were observed between subjects with the various APOE genotypes.

When we restricted the study population to persons with a known serum apoE level \( n=1194 \), we found that serum apoE level was not associated with common carotid artery intima-media thickness (age- and sex-adjusted \( \beta=0.002 \); SE=0.009; \( P=0.80 \)). Furthermore, similar associations were found of APOE with the presence of a plaque at 1 of the 3 locations in the carotid arterial tree, and we therefore analyzed the total number of plaques at all sides. We found that increasing serum apoE levels slightly increased the OR for <4 plaques (OR=1.3 for every mmol/mL increase; 95% CI, 0.9 to 2.1), but this was not statistically significant (\( P=0.21 \)). The OR for >3 plaques was 1.8 for every mmol/mL increase (95% CI, 0.9 to 3.4; \( P=0.08 \)). Analyses with both the APOE genotype and serum apoE levels in the model slightly strengthened the relationships of both determinants with carotid plaques and intima-media thickness (data not shown).
TABLE 3. OR for Plaques in Carotid Arteries in Relation to APOE Genotypes

<table>
<thead>
<tr>
<th>No. of Plaques</th>
<th>E2E2</th>
<th>E2E3</th>
<th>E2E4</th>
<th>E3E3</th>
<th>E3E4</th>
<th>E4E4</th>
</tr>
</thead>
<tbody>
<tr>
<td>All</td>
<td>1.0 (0.4 to 2.2)</td>
<td>0.9 (0.7 to 1.1)</td>
<td>0.9 (0.6 to 1.4)</td>
<td>1 (reference)</td>
<td>1.1 (0.9 to 1.2)</td>
<td>0.7 (0.4 to 1.1)</td>
</tr>
<tr>
<td>1–3, model 1</td>
<td>1.0 (0.4 to 2.3)</td>
<td>0.9 (0.8 to 1.2)</td>
<td>0.9 (0.6 to 1.4)</td>
<td>1 (reference)</td>
<td>1.0 (0.9 to 1.2)</td>
<td>0.7 (0.4 to 1.1)</td>
</tr>
<tr>
<td>Affected/observations</td>
<td>14/31 (45%)</td>
<td>254/558 (46%)</td>
<td>44/107 (41%)</td>
<td>1103/2506 (44%)</td>
<td>434/966 (45%)</td>
<td>35/105 (33%)</td>
</tr>
<tr>
<td>All</td>
<td>1.0 (0.3 to 3.0)</td>
<td>0.6 (0.4 to 0.8)†</td>
<td>0.9 (0.5 to 1.7)</td>
<td>1 (reference)</td>
<td>1.0 (0.8 to 1.3)</td>
<td>1.4 (0.8 to 2.4)</td>
</tr>
<tr>
<td>4–6, model 2</td>
<td>1.2 (0.4 to 3.7)</td>
<td>0.6 (0.5 to 0.9)*</td>
<td>1.0 (0.5 to 1.8)</td>
<td>1 (reference)</td>
<td>1.0 (0.8 to 1.2)</td>
<td>1.3 (0.7 to 2.2)</td>
</tr>
<tr>
<td>Affected/observations</td>
<td>6/31 (19%)</td>
<td>64/558 (12%)</td>
<td>19/107 (18%)</td>
<td>438/2506 (18%)</td>
<td>164/966 (17%)</td>
<td>26/105 (25%)</td>
</tr>
<tr>
<td>Men</td>
<td>0.7 (0.2 to 3.5)</td>
<td>1.0 (0.7 to 1.4)</td>
<td>0.7 (0.3 to 1.4)</td>
<td>1 (reference)</td>
<td>1.0 (0.8 to 1.3)</td>
<td>1.0 (0.8 to 1.3)</td>
</tr>
<tr>
<td>1–3, model 1</td>
<td>0.9 (0.2 to 4.2)</td>
<td>1.0 (0.7 to 1.4)</td>
<td>0.7 (0.3 to 1.4)</td>
<td>1 (reference)</td>
<td>1.0 (0.8 to 1.3)</td>
<td>1.0 (0.5 to 1.9)</td>
</tr>
<tr>
<td>Affected/observations</td>
<td>4/13 (31%)</td>
<td>103/208 (50%)</td>
<td>18/46 (39%)</td>
<td>472/1041 (45%)</td>
<td>180/368 (47%)</td>
<td>20/49 (41%)</td>
</tr>
<tr>
<td>Men</td>
<td>2.7 (0.6 to 12.1)</td>
<td>0.7 (0.4 to 1.1)</td>
<td>0.9 (0.4 to 2.1)</td>
<td>1 (reference)</td>
<td>0.9 (0.7 to 1.3)</td>
<td>1.5 (0.7 to 3.4)</td>
</tr>
<tr>
<td>4–6, model 2</td>
<td>3.3 (0.7 to 15.1)</td>
<td>0.7 (0.4 to 1.1)</td>
<td>0.9 (0.4 to 2.1)</td>
<td>1 (reference)</td>
<td>0.9 (0.6 to 1.3)</td>
<td>1.5 (0.7 to 3.3)</td>
</tr>
<tr>
<td>Affected/observations</td>
<td>6/13 (46%)</td>
<td>31/208 (15%)</td>
<td>11/46 (24%)</td>
<td>226/1041 (22%)</td>
<td>76/386 (20%)</td>
<td>14/49 (29%)</td>
</tr>
<tr>
<td>Women</td>
<td>1.1 (0.4 to 2.8)</td>
<td>0.8 (0.7 to 1.1)</td>
<td>1.1 (0.6 to 1.9)</td>
<td>1 (reference)</td>
<td>1.1 (0.9 to 1.3)</td>
<td>0.5 (0.3 to 1.0)</td>
</tr>
<tr>
<td>1–3, model 2</td>
<td>1.1 (0.4 to 2.9)</td>
<td>0.9 (0.7 to 1.2)</td>
<td>1.1 (0.6 to 2.0)</td>
<td>1 (reference)</td>
<td>1.0 (0.8 to 1.3)</td>
<td>0.5 (0.3 to 1.0)</td>
</tr>
<tr>
<td>Affected/observations</td>
<td>10/18 (56%)</td>
<td>151/350 (43%)</td>
<td>26/61 (43%)</td>
<td>631/1465 (43%)</td>
<td>254/580 (44%)</td>
<td>15/56 (27%)</td>
</tr>
</tbody>
</table>

Values are ORs with 95% CIs adjusted for age and sex (model 1) or age, sex, and total and HDL cholesterol (model 2).

*Significantly different from E3E3 group: P<0.05.
†Significantly different from E3E3 group: P<0.005.

Discussion

In this large population-based study, we found that the E2E3 genotype was inversely related to plaques in the carotid arteries and with the intima-media thickness of the common carotid arteries. These inverse associations did not weaken when adjustments were made for serum apoE and total or HDL cholesterol. We did not find an association between E3E4 and carotid artery atherosclerosis. Atherosclerosis was slightly more prevalent in the E4E4 group, although these associations never reached statistical significance. Inconsistent findings were observed in the E2E2 and E2E4 groups.

A limitation of this study is the cross-sectional design because it could be hypothesized that selective survival may have occurred. However, when we restricted the study population to persons in whom mortality may be less important (ie, younger persons with no evidence of vascular diseases or vascular risk factors), similar findings were obtained (not shown). Furthermore, inconsistent findings have emerged from studies on APOE and survival. In the Rotterdam Study, APOE was not related with mortality during follow-up. This indicates that selective survival did not play a major role.

An advantage of this study is the population-based approach that included institutionalized subjects with a high response rate. Of concern is the exclusion of persons with missing data. However, when we compared subjects from our study population with other, excluded participants in the Rotterdam Study, we did not observe consistent differences with regard to cardiovascular risk indicators (not shown). Selection bias seems therefore not to be likely, and our findings can be generalized to the general elderly population.

We estimated the presence of atherosclerosis by established, validated techniques. First, the presence of atherosclerosis was found to be increased in APOE*4 carriers and to be decreased in carriers of the APOE*2 allele. This was observed in an autopsy study and confirmed in a study on subjects referred to an atherosclerosis prevention clinic, who had no plaque or stenosis in the carotid wall and who were free from cardiovascular disease. Second, an increased risk of atherosclerosis has been found in relation to APOE*2. This was suggested by the Atherosclerosis Risk in Communities (ARIC) Study among subjects free from cardiovascular disease. We also observed that selective survival did not play a major role.
vascular disease.\textsuperscript{20} Third, no association between APOE and atherosclerosis has been reported. These findings refer to 2 investigations on ultrasonographically assessed intima-media thickness of subjects without evidence for vascular disease.\textsuperscript{19,21} All previous studies thus excluded persons with highest risk of vascular disease, and because few of them were population-based,\textsuperscript{17,18} these findings are subject to selection bias and cannot be generalized to the general population.

Our observation that APOE*2 carriers have in serum higher levels of apoE and HDL cholesterol and lower levels of total cholesterol and that APOE*4 has opposite effects is in agreement with earlier reports.\textsuperscript{2–4} However, adjustment for serum apoE level or for total and HDL cholesterol did not weaken the inverse association of E2E3 with carotid artery atherosclerosis. Because the effects of E2E3 on atherosclerosis seem therefore not to result from its effects on serum apoE or cholesterol levels, the E2E3 genotype may protect from atherosclerosis through alternative pathways.

Atherosclerosis is associated with increased oxidative stress, since the oxidative modification of LDL seems to be a crucial step in its development.\textsuperscript{35} The various apoE isoforms have been found to exert different antioxidant effects.\textsuperscript{36} Furthermore, because apoE seems to have several other properties with relevance to vessel wall homeostasis, including the modulation of platelet aggregability and the proliferation and migration of smooth muscle cells and lymphocytes,\textsuperscript{5,37} it is possible that these properties may differ across the apoE isoforms.

In conclusion, we found that APOE*4 was only weakly and nonstatistically significantly related to atherosclerosis in the carotid arteries. By contrast, an inverse relationship between the E2E3 genotype and carotid artery atherosclerosis was observed, which was independent of serum apoE and total and HDL cholesterol levels. However, the low E2E3 frequency, together with the small effects, implies that any protective effect is limited.

Acknowledgements

This study was supported by the NESTOR stimulation program for geriatric research in the Netherlands (Ministry of Health and Ministry of Education), the Netherlands Organization for Scientific Research (NWO), the Netherlands Prevention Fund, the municipality of Rotterdam, and the Fund for Scientific Research (FWO-F), Flanders, Belgium. Dr Havekes is supported by Biomed (BMH4-CT96-0898) from the specific RTD program of the European Community. Dr Crtus is a postdoctoral fellow of the FWO-F. Katinka Grashuis is acknowledged for scoring of aorta calcifications on radiographic films. We thank Jeanette Vergeer, Bianca de Graaf, and Angela Jacobs for isolating DNA and Hubert Backhovens, Marleen Van den Broeck, and Sally Serneels for APOE genotyping.

References


